ECSP22084245A - Compuestos y métodos dirigidos a interleucina-34 - Google Patents

Compuestos y métodos dirigidos a interleucina-34

Info

Publication number
ECSP22084245A
ECSP22084245A ECSENADI202284245A ECDI202284245A ECSP22084245A EC SP22084245 A ECSP22084245 A EC SP22084245A EC SENADI202284245 A ECSENADI202284245 A EC SENADI202284245A EC DI202284245 A ECDI202284245 A EC DI202284245A EC SP22084245 A ECSP22084245 A EC SP22084245A
Authority
EC
Ecuador
Prior art keywords
compounds
methods targeting
targeting interleukin
methods
interleukin
Prior art date
Application number
ECSENADI202284245A
Other languages
English (en)
Inventor
Victor H Obungu
Marcio Chedid
Andrew Dixon Skora
Ming Ye
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22084245A publication Critical patent/ECSP22084245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos IL-34, composiciones que los comprenden y métodos para usar los anticuerpos y/o composiciones de estos para tratar enfermedades mediadas por el sistema inmunitario tales como enfermedades neurodegenerativas, por ejemplo, la enfermedad de Alzheimer o una enfermedad de tauopatía.
ECSENADI202284245A 2020-04-30 2022-10-28 Compuestos y métodos dirigidos a interleucina-34 ECSP22084245A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063017748P 2020-04-30 2020-04-30

Publications (1)

Publication Number Publication Date
ECSP22084245A true ECSP22084245A (es) 2022-11-30

Family

ID=75905053

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202284245A ECSP22084245A (es) 2020-04-30 2022-10-28 Compuestos y métodos dirigidos a interleucina-34

Country Status (18)

Country Link
US (3) US11649280B2 (es)
EP (1) EP4142880A1 (es)
JP (2) JP7696367B2 (es)
KR (1) KR20230003187A (es)
CN (1) CN115867576A (es)
AR (1) AR121898A1 (es)
AU (1) AU2021264421B2 (es)
BR (1) BR112022021743A2 (es)
CA (1) CA3176669A1 (es)
CO (1) CO2022015893A2 (es)
CR (1) CR20220557A (es)
EC (1) ECSP22084245A (es)
IL (1) IL297638A (es)
JO (1) JOP20220285A1 (es)
MX (1) MX2022013617A (es)
PE (1) PE20231030A1 (es)
TW (1) TWI799840B (es)
WO (1) WO2021222025A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121898A1 (es) * 2020-04-30 2022-07-20 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34
IL312380A (en) * 2021-10-29 2024-06-01 Lilly Co Eli Compounds and methods targeting interleukin-34
MX2024005144A (es) * 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
US20260125460A1 (en) * 2021-10-29 2026-05-07 Eli Lilly And Company Compounds and methods targeting interleukin-34
CN116970567A (zh) * 2023-05-11 2023-10-31 宁波熙宁检测技术有限公司 一种稳转细胞株、构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
EP3174895A1 (en) 2014-07-28 2017-06-07 Nogra Pharma Limited Methods and compositions for diagnosing and treating inflammatory bowel disorders
ES2870983T3 (es) 2014-12-19 2021-10-28 Univ Nantes Anticuerpos anti-IL-34
HK1249016A1 (zh) * 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
EP3758736B1 (en) 2018-03-02 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Il-34 for use in a method of treating retinal inflammation and neurodegeneration
AR121898A1 (es) * 2020-04-30 2022-07-20 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34

Also Published As

Publication number Publication date
CO2022015893A2 (es) 2022-11-18
JP7696367B2 (ja) 2025-06-20
TW202206458A (zh) 2022-02-16
KR20230003187A (ko) 2023-01-05
JP2025081355A (ja) 2025-05-27
US20240141033A1 (en) 2024-05-02
WO2021222025A1 (en) 2021-11-04
MX2022013617A (es) 2022-11-16
CA3176669A1 (en) 2021-11-04
US20210363232A1 (en) 2021-11-25
CR20220557A (es) 2022-11-28
CN115867576A (zh) 2023-03-28
BR112022021743A2 (pt) 2022-12-06
PE20231030A1 (es) 2023-07-10
AU2021264421A1 (en) 2022-11-24
JP2023524515A (ja) 2023-06-12
AR121898A1 (es) 2022-07-20
JOP20220285A1 (ar) 2022-10-30
TWI799840B (zh) 2023-04-21
AU2021264421B2 (en) 2024-11-07
US20230279098A1 (en) 2023-09-07
US11649280B2 (en) 2023-05-16
EP4142880A1 (en) 2023-03-08
IL297638A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CO2022015893A2 (es) Compuestos y métodos dirigidos a interleucina-3
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
CO2021005987A2 (es) Compuestos de anillo fusionado
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
CL2020001070A1 (es) Composiciones de péptidos tau fosforilados y sus usos.
UY38476A (es) Inhibidores de arg1 y/o arg2
JOP20230036A1 (ar) نواهض مستقبل أوريكسين بيروليدين سيكلوهيبتان
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
CO2022006708A2 (es) Anticuerpos trem2 y usos de estos
CO6640211A2 (es) Composiciones del péptido a-beta y métodos
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2021015501A (es) Anticuerpos y metodos de uso.
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX2019013524A (es) Composiciones para tratar enfermedades neurodegenerativas.
CO2024005417A2 (es) Compuestos y métodos dirigidos a la interleucina-34
BR112022012153A2 (pt) Processo para preparar um composto e composto
MX2023008108A (es) Proteina de lectina para tratamiento y prevencion de enfermedades neurodegenerativas.
MX2024005145A (es) Compuestos y metodos dirigidos a la interleucina-34.
MX2024005144A (es) Compuestos y metodos dirigidos a la interleucina-34.